Key facts
- This page summarizes Patrick Soon-Shiong's Form 4 filing for ImmunityBio, Inc. (IBRX).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 24 Feb 2026, 20:05.
Patrick Soon-Shiong - 22 Feb 2026 Form 4 Insider Report for ImmunityBio, Inc. (IBRX)
- Reporting relationship
- Founder, Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner
- Issuer ticker
- IBRX
- Reported as of
- 22 Feb 2026
- Net transaction value
- -$506,079
- SEC form
- 4
- Accepted by SEC
- 24 Feb 2026, 20:05:07 UTC
- Prior SEC filing
- 12 Feb 2026
- Next SEC filing
- 02 Apr 2026
- Source filing
- View source filing
- Reporting owner signature
-
/s/ Patrick Soon-Shiong, /s/ Charles Kenworthy, Manager of MP 13 Ventures, on behalf of itself and as General Partner of Cambridge Equities, and /s/ Charles Kenworthy, Manager of California Capital Equity and Manager...
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Patrick Soon-Shiong filed Form 4 for ImmunityBio, Inc. (IBRX) on 24 Feb 2026.
Change
- Previous filing in this sequence was filed on 12 Feb 2026.
- Current net transaction value: -$506,079.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (5)
CIK 0001189020
Primary reporting owner
SOON-SHIONG PATRICK
- Relationship
- Founder, Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner
- Address
- C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO
- Signature
- /s/ Patrick Soon-Shiong, /s/ Charles Kenworthy, Manager of MP 13 Ventures, on behalf of itself and as General Partner of Cambridge Equities, and /s/ Charles Kenworthy, Manager of California Capital Equity and Manager of Nant Capital
- Signature date
- 24 Feb 2026
CIK 0001517764
CALIFORNIA CAPITAL EQUITY, LLC
- Relationship
- 10%+ Owner
- Address
- 450 DULEY ROAD, EL SEGUNDO
- Signature
- /s/ Patrick Soon-Shiong, /s/ Charles Kenworthy, Manager of MP 13 Ventures, on behalf of itself and as General Partner of Cambridge Equities, and /s/ Charles Kenworthy, Manager of California Capital Equity and Manager of Nant Capital
- Signature date
- 24 Feb 2026
CIK 0001629222
Cambridge Equities, LP
- Relationship
- 10%+ Owner
- Address
- 450 DULEY ROAD, EL SEGUNDO
- Signature
- /s/ Patrick Soon-Shiong, /s/ Charles Kenworthy, Manager of MP 13 Ventures, on behalf of itself and as General Partner of Cambridge Equities, and /s/ Charles Kenworthy, Manager of California Capital Equity and Manager of Nant Capital
- Signature date
- 24 Feb 2026
CIK 0001629186
MP 13 Ventures, LLC
- Relationship
- 10%+ Owner
- Address
- 450 DULEY ROAD, EL SEGUNDO
- Signature
- /s/ Patrick Soon-Shiong, /s/ Charles Kenworthy, Manager of MP 13 Ventures, on behalf of itself and as General Partner of Cambridge Equities, and /s/ Charles Kenworthy, Manager of California Capital Equity and Manager of Nant Capital
- Signature date
- 24 Feb 2026
CIK 0001675758
Nant Capital, LLC
- Relationship
- 10%+ Owner
- Address
- 450 DULEY ROAD, EL SEGUNDO
- Signature
- /s/ Patrick Soon-Shiong, /s/ Charles Kenworthy, Manager of MP 13 Ventures, on behalf of itself and as General Partner of Cambridge Equities, and /s/ Charles Kenworthy, Manager of California Capital Equity and Manager of Nant Capital
- Signature date
- 24 Feb 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
IBRX
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +114,329
- Change %
- +0.38%
- Price
- $0.000000
- Shares after
- 29,816,081
- Date
- 22 Feb 2026
- Ownership
- Direct
- Footnotes
- F1
IBRX
transaction
Common Stock
Tax liability
- Transaction value
- $506,079
- Shares
- -58,170
- Change %
- -0.2%
- Price
- $8.70
- Shares after
- 29,757,911
- Date
- 22 Feb 2026
- Ownership
- Direct
- Footnotes
- F2
IBRX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 246,412,277
- Date
- 22 Feb 2026
- Ownership
- See footnote
- Footnotes
- F3
IBRX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 261,705,814
- Date
- 22 Feb 2026
- Ownership
- See footnote
- Footnotes
- F4
IBRX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 8,383,414
- Date
- 22 Feb 2026
- Ownership
- See footnote
- Footnotes
- F5
IBRX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 7,976,159
- Date
- 22 Feb 2026
- Ownership
- See footnte
- Footnotes
- F6
IBRX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 5,618,326
- Date
- 22 Feb 2026
- Ownership
- See footnote
- Footnotes
- F7
IBRX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 9,986,920
- Date
- 22 Feb 2026
- Ownership
- See footnote
- Footnotes
- F8
IBRX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 47,557,934
- Date
- 22 Feb 2026
- Ownership
- See footnote
- Footnotes
- F9
IBRX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 32,606,985
- Date
- 22 Feb 2026
- Ownership
- See footnote
- Footnotes
- F10
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
IBRX
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -114,329
- Change %
- -50%
- Price
- $0.000000
- Shares after
- 114,329
- Date
- 22 Feb 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 114,329
- Exercise price
- Footnotes
- F1, F11
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 11 footnotes
Footnote F1
Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock.
Footnote F2
On February 22, 2026, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on February 20, 2026 was the settlement price used to calculate the shares withheld.
Footnote F3
Shares held by Nant Capital, LLC, an investment vehicle of the Reporting Person ("Nant Capital").
Footnote F4
Shares held by Cambridge Equities, LP ("Cambridge Equities"). MP 13 Ventures, LLC ("MP 13 Ventures") is the general partner of Cambridge Equities and may be deemed to have beneficial ownership of the shares held by Cambridge Equities. The Reporting Person is the sole member of MP 13 Ventures and has voting and dispositive power over the shares held by Cambridge Equities.
Footnote F5
Shares held by NantBio, Inc. ("NantBio"). NantWorks, LLC ("NantWorks") is the majority stockholder and an affiliate of NantBio and may be deemed to have beneficial ownership of the shares held by NantBio. The Reporting Person is the chief executive officer of NantWorks and indirectly beneficially owns all of the equity interests in NantWorks and may be deemed to have voting and dispositive power over the shares held by NantBio.
Footnote F6
Shares held by California Capital Equity, LLC ("CalCap"). The Reporting Person owns all of the equity interests of CalCap and has voting and dispositive power over the shares held by CalCap.
Footnote F7
Shares held by the Chan Soon-Shiong Family Foundation, an exempt corporation organized under the laws of the State of Delaware (the "Foundation"). The Foundation has the sole power to vote and direct the disposition of all shares directly owned by the Foundation, except to the extent it may be deemed to share such power with the Reporting Person by virtue of the reporting person's control over the Foundation. The rReporting Person serves as Chairman of the Foundation.
Footnote F8
Shares held by NantWorks. CalCap directly owns all of the equity interests of NantWorks and may be deemed to have beneficial ownership of the securities held by NantWorks. The Reporting Person directly owns all of the equity interests of CalCap and may be deemed to have voting and dispositive power over the securities held by NantWorks.
Footnote F9
Shares held by NantMobile, LLC ("NantMobile"). NantWorks, LLC ("NantWorks") is the majority stockholder and an affiliate of NantMobile and may be deemed to have beneficial ownership of the securities held by NantMobile. The reporting person is the chief executive officer of NantWorks and indirectly beneficially owns all of the equity interests in NantWorks and may be deemed to have voting and dispositive power over the securities held by NantMobile.
Footnote F10
Shares held by NantCancerStemCell, LLC ("NantCancerStemCell"). NantBio is the majority stockholder and an affiliate of NantCancerStemCell and may be deemed to have beneficial ownership of the securities held by NantCancerStemCell. NantWorks is the majority stockholder and an affiliate of NantBio and may be deemed to have beneficial ownership of the securities held by NantBio and its affiliates. The Reporting Person is the chief executive officer of NantWorks and indirectly beneficially owns all of the equity interests in NantWorks and may be deemed to have voting and dispositive power over the securities held by NantBio and its affiliates.
Footnote F11
Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024.
SEC remarks
Founder, Executive Chairman, Global Chief Scientific and Medical Officer